Mizuho lowered the firm’s price target on Immunocore (IMCR) to $33 from $38 and keeps a Neutral rating on the shares. The firm’s thesis on Immunocore remains unchanged, and while Mizuho views Immunocre as a pioneer and leader in the development of T-cell receptor-based therapeutics for cancer, overall lack of meaningful clinical newsflow over the next 12-15 months for the company makes it difficult to see why its shares should outperform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore Holdings: Buy Rating Backed by Promising Strategy and Strong Financials Despite Mixed Study Data
- Immunocore Holdings’ Promising HIV Immunotherapy Advances Justify Buy Rating
- Positive Outlook on Immunocore Holdings’ Innovative HIV Program Justifies Buy Rating
- Immunocore Holdings Reveals Promising HIV Trial Results
- Immunocore assumed with an Equal Weight at Morgan Stanley